Ignacio Bernabéu

A consensus on the diagnosis and treatment of acromegaly complications

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

Cushing's syndrome

The JAK/STAT signaling pathway: from bench to clinic

Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients

Acromegaly: An Endocrine Society Clinical Practice Guideline

Diagnosis and Complications of Cushing’s Syndrome: A Consensus Statement

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

Pegvisomant Treatment in Acromegaly

Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists

Guidelines for Perioperative Care in Elective Rectal/Pelvic Surgery: Enhanced Recovery After Surgery (ERAS^®) Society Recommendations

Menstrual Abnormalities in Women with Cushing’s Disease Are Correlated with Hypercortisolemia Rather Than Raised Circulating Androgen Levels

Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert’s Syndrome

Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre S panish study

Pegvisomant and cabergoline combination therapy in acromegaly

Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)

Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

Anterior Pituitary Function in Cushing's Syndrome: Study of 36 Patients.